舒洛地特软胶囊辅助治疗糖尿病下肢血管病变的疗效及对血液流变学的影响

Curative Effect of Sulodexide Soft Capsule Adjuvant Therapy on Lower-Extremity Arterial Disease and Its Influences on Hemorheology

目的探讨舒洛地特软胶囊辅助治疗糖尿病下肢血管病变的疗效及对血液流变学的影响。方法将我院2018年9月至2019年5月收治的100例糖尿病下肢血管病变患者随机分为两组,各50例。甲组采用常规治疗,乙组在甲组基础上联合舒洛地特软胶囊治疗,两组均治疗4周,比较两组治疗后临床疗效、行走距离及治疗前后血液流变学指标变化。结果治疗后,乙组临床有效率高于甲组(P<0.05);治疗后两组无痛行走距离、最大行走距离均较治疗前显著增加,且乙组优于甲组(P<0.05);治疗后两组全血高切黏度(HSV)、全血低切黏度(LSV)、血浆黏度(PSV)、血细胞比容(HCT)、血小板聚集率均明显下降(P<0.05),且乙组较甲组明显低(P<0.05)。结论舒洛地特软胶囊辅助治疗糖尿病下肢血管病变的疗效好,可有效增加患者行走距离及改善血液流变学。

Objective To explore the curative effect of sulodexide soft capsule adjuvant therapy on lower-extremity arterial disease(LEAD) and its influences on hemorheology. Methods A total of 100 LEAD patients who were admitted to the hospital from September 2018 to May 2019 were randomly divided into group A(routine treatment) and group B(routine treatment and sulodexide soft capsules), 50 cases in each group. Both groups were treated for 4 weeks. The clinical curative effect after treatment, painless walking distance and maximum walking distance, and changes of hemorheology indexes before and after treatment were compared between the two groups. Results After treatment, the clinical response rate of group B was higher than that of group A(P<0.05). After treatment, painless walking distance and maximum walking distance in both groups were significantly increased, which were better in group B than group A(P<0.05). After treatment, whole blood high shear viscosity(HSV), whole blood low shear viscosity(LSV), plasma viscosity(PSV), hematocrit(HCT) and platelet aggregation rate in both groups were significantly decreased(P<0.05), which were significantly lower in group B than group A(P<0.05). Conclusion Curative effect of sulodexide soft capsule adjuvant therapy is good on LEAD, which can effectively increase walking distance and improve hemorheology.